New Strategies for carcinoma of unknown primary: The role of tissue-of-origin molecular profiling

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4027-4033

  Varadhachary, Gauri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; MICRORNA;

ALGORITHM; ARTICLE; ASSAY; CANCER CLASSIFICATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; PATHOLOGIST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE OF ORIGIN MOLECULAR PROFILING; BIOPSY; CARCINOMA; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS, UNKNOWN PRIMARY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

BIOPSY; CARCINOMA; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, UNKNOWN PRIMARY; TREATMENT OUTCOME;

EID: 84881256279     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3030     Document Type: Article

References (37)

1. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009;36:8-37.
2. Rubin BP, Skarin AT, Pisick E, Rizk M, Salgia R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev 2001;10:77-82.
3. Krishna M. Diagnosis of metastatic neoplasms: an immunohistochemical approach. Arch Pathol Lab Med 2010;134:207-15.
4. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profilechanging paradigm and emerging definitions. Lancet Oncol 2008; 6:596-9.
5. Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol 2012;23:271-7.
6. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007;43:2026-36.
7. National Comprehensive Cancer Network; Occult Primary (Cancer of Unknown Primary) version 1.2013 [cited 2013 Jan 1]. Available from: www.nccn.org
8. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18FFDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35: 1076-82.
9. Rudmik L, Lau HY, Matthews TW, Bosch JD, Kloiber R, Molnar CP, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 2011;33:935-40.
10. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004;101: 2641-9.
11. Joshi U, van der Hoeven JJ, Comans EF, Herder GJ, Teule GJ, Hoekstra OS. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDGPET. Br J Radiol 2004;77:1000-6.
12. Møller AK, Loft A, Berthelsen AK, Pedersen KD, Graff J, Christensen CB, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 2012;17:1146-54.
13. Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol 2009;36:38-43.
14. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001;98:15149-54.
15. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al., Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-93.
16. Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004;164:9-16.
17. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031-40.
18. Ma XJ, Patel R, Wang X, Salunga R, Murage J, Desai R, et al. Molecular classification of human cancers using a 92-gene realtime quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-73.
19. Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 2012;18: 3952-60.
20. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009;27:2503-8.
21. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 2011;13:48-56.
22. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011;225:43-53.
23. Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23: 814-23.
24. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012;17:801-12.
25. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008;26:4442-8.
26. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008;26:4435-41.
27. Gross-Goupil M, Massard C, Lesimple T, Merrouche Y, Blot E, Loriot Y, et al. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie 2012;35:54-5.
28. Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011;17:4063-70.
29. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010;15:500-6.
30. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J Clin Oncol 2013;31:217-23
31. Carlson H, Lenzi R, Raber MN, Varadhachary GR. A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol 2013;18:226-31.
32. Institute of Medicine. Evolution of translational omics: lessons learned and the path forward [cited 2012 Dec 20]. National Academies Press, Washington, DC; 2012. Available from: www.iom.edu
33. FDA/CDRH Public Meeting. Oversight of laboratory developed tests (LDTs); 2010 [cited 2013 Feb 25]. Available from: http://www.fda.gov/ MedicalDevices/NewsEvents/WorkshopsConferences
34. Hale KS, Wang H, Karanth S, Raber MN, Carlson HR, Lenzi R, et al. Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. J Clin Oncol 2012;30 (Suppl; abstr 4131).
35. Handorf CR, Kulkarni A, Ezekiel AM, Grenert JP, Kim OS, Rogers WM, et al. Cancer of uncertain origin: comparative effectiveness of immunohistochemistry and gene expression profiling in diagnosing the primary site in metastatic cancer. J Mol Diagn 2012;14:716 (abstract:ST75).
36. Weiss L, Chu P, Schroeder BE, Singh V, Zhang Y, Erlander ME, et al. Immunohistochemistry (IHC) vs a 92-gene cancer classifier in the diagnosis of primary site in metastatic tumors: a blinded comparator study. J Mol Diagn 2012;14:721 (abstract: ST96).
37. Kulkarni A, Pillai R, Ezekiel AM, Henner WD, Handorf CR. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer. Diagn Pathol 2012;7:110.